Details for Patent: 10,993,914

Which drugs does patent 10,993,914 protect, and when does it expire?

Patent 10,993,914 protects ONIVYDE and is included in one NDA.

This patent has thirty-nine patent family members in nineteen countries.

Summary for Patent: 10,993,914

Title:	Stabilizing camptothecin pharmaceutical compositions
Abstract:	Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.
Inventor(s):	Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'brien
Assignee:	Ipsen Biopharm Ltd
Application Number:	US16/567,902
Patent Claim Types: see list of patent claims	Composition; Process; Dosage form;

Drugs Protected by US Patent 10,993,914

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ipsen	ONIVYDE	irinotecan hydrochloride	INJECTABLE, LIPOSOMAL;INTRAVENOUS	207793-001	Oct 22, 2015		RX	Yes	Yes			Y

International Family Members for US Patent 10,993,914

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016340153
Australia	2022203167
Brazil	112018006922
Brazil	122021024957
Canada	3001467
China	108366965